Closure of NUS-IRB Office from 13 - 14 January 2020
The NUS-IRB office will be closed on the above days, in view of staff training and intensive involvement with the implementation of the upcoming iRIMS (Integrated Research Information Management Suite) system. During this time no applications can be processed by the IRB Secretariat. We apologise for the inconvenience caused and seek your understanding and patience during this time, thank you.
COMPUTERIZATION OF IRB PROCESSES
Dear IRB applicants,
We are in the process of migrating our current processing of IRB applications to an online IRB application system. The system should be ready in Feb 2020. Hopefully it will speed up the processing of IRB applications in the future.
During this period, we regret that there will be substantial delays in the processing of IRB applications. Researchers are kindly advised to submit their IRB applications earlier or channel their SBER applications (that are minimal risk and qualify for IRB exemption) to the Department Ethics Review Committee (DERC) if they need an urgent review. (see also News Alert #26)
Please contact the NUS-IRB at 65164311 or firstname.lastname@example.org for further information and assistance. Thank you.
NUS RCIO ANNOUNCEMENT ON CONSENT-TAKING, TISSUE BANKING, AND INCIDENTAL FINDINGS POLICY UPDATES
With the expiry of HBR consent-taking exemptions, activation of Tissue Banking Regulations and related regulatory amendments effective 1 Nov 2019, the Research Compliance and Integrity Office (RCIO) has issued an announcement on appropriate consents, NUS Tissue Bank principal person-in-charge (PIC), and updates to their Incidental Findings policy. Please refer to RCIO's website for more details. Researchers may reach out to email@example.com for enquiries on the above announcement and updated policy.
Updates on the tissue banking regulations can be accessed from the Singapore Ministry of Health (MOH)'s webpage here.
JOINT WORKSHOP BY CDTL-ALSET: LEARNING & ANALYTICS COMMITTEE ON ETHICS (LACE)
Thank you for attending the joint workshop organised by the Centre for Development of Teaching and Learning (CDTL) and Institute for the Application of Learning Science & Educational Technology (ALSET).
The slides presented by NUS-IRB can be accessed: here
Slides presented by ALSET will be uploaded upon receiving their agreement.
1. "ETHICS REVIEW OF FACULTY RESEARCH BY DERC" GUIDELINES
With effect from 1 June 2019, some faculty research can be reviewed by the Departmental Ethics Review Committee (DERC). Please refer to the new guidelines on "Ethics review of faculty research by DERC" for more information.
2. NEW FORMS AND GUIDELINES ON SERIOUS ADVERSE EVENTS, NON-COMPLIANCE/ DEVIATION AND (UN)EXPECTED EVENTS
Three new forms and their guidelines have been uploaded for researchers' use. Please refer to the "Forms" tab.
SHARING SESSION: FACULTY RESEARCH TO BE REVIEWED BY DERC
Thank you everyone who turned up for the IRB Sharing Session on 14 May 2019. We hope it was a good sharing session for you. The presentation slides are available for download at this link - SLIDES
IN VIEW OF THE RECENT CHANGES MENTIONED BELOW, THE APPLICATION REVIEW TIMELINE HAS BEEN REVISED.
Researchers are strongly advised to plan and submit their IRB applications well in advance in anticipation of the long processing queue. Please click here to see the revised timeline.
1. END OF TRANSITIONAL PERIOD FOR THE HUMAN BIOMEDICAL RESEARCH (HBR) FRAMEWORK
The human biomedical research regulatory framework of the Human Biomedical Research Act (HBRA) comes into full effect on 1 Nov 2018. All human biomedical research activities must then be fully compliant with the HBRA and any such activities which are not compliant, should cease.
Please refer to our revised Human Biomedical Research IRB Application Form and new Guidelines for your HBR applications.
2. IMPLEMENTATION OF VALIDITY PERIOD FOR IRB-APPROVED STUDIES FROM 1 Nov 2018
From 1 Nov 2018, the NUS-IRB has implemented a 1-year validity or all HBR conducted in NUS.
All Social, Behavioural and Educational Research (SBER) will have a 1-year or 3-year approval period, depending on the risk of the research study.
Please refer to our latest news alert for more information.